Navigation Links
5,000 Patients Treated With OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
Date:11/8/2007

Enrollment Reaches Milestone as Interim Data Show Pro-Healing Stent

Performs Comparably to Drug-Eluting Stents

HONG KONG, Nov. 8 /PRNewswire/ -- OrbusNeich today reported that 5,000 patients treated with the company's Genous stent at more than 120 sites in 29 countries are now enrolled in the global e-HEALING registry.

OrbusNeich's e-HEALING clinical study is a monitored multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio-engineered R stent. The study protocol recommends that patients receive one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary endpoint of the registry is target vessel failure at 12 months.

"We reached this significant enrollment milestone earlier than we expected," said Sigmund Silber, M.D., F.A.C.C., F.E.S.C., professor of medicine, a co-principal investigator of the study. "This reflects an increase in demand and use for Genous by physicians concerned with drug- eluting stents."

Robbert de Winter, M.D., Ph.D., F.E.S.C., a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, added: "We look forward to our continued reporting of the patient follow-up data. Our next presentation is expected to be at the American College of Cardiology's annual scientific session early next year."

Unlike drug-eluting stents, Genous is coated with an antibody that captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

"Completing enrollment in this large registry is an important milestone in our clinical development," said Samuel Rasmussen, OrbusNeich's president and CEO.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. In addition to Genous OrbusNeich's products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
2. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
3. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
4. Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations
5. Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home
6. TriWest Contributes $25,000 to Iowa National Guard Fund and Sponsors Education for Teachers of Military Children
7. 18th Annual CATCH Night of Champions Raises $225,000 To Help Support Local Youth
8. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
9. Comparison of obstetric outcomes between on-call and patients own obstetricians
10. Vision restoration therapy shown to improve brain activity in brain injured patients
11. Diabetes appears to increase risk of death for patients with acute coronary syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD ... a benign bony lump located on the forehead usually attributed to a facial fracture. ... and pain. Dr. Shah has discovered an approach that is minimally invasive. He is ...
(Date:4/21/2017)... Horsham, PA (PRWEB) , ... April 21, 2017 , ... ... The new identity emphasizes the agency’s conviction that the full potential of specialty and ... HCPs are equally appreciated and aligned. , “The Unifying Effect is at the ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) ... facility among higher education institutions in Hong Kong to support teaching, learning and research. ... range and quantity of facilities in Hong Kong. , With an area of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway Management, the medical device ... highly regarded and well renowned Asian distributor, Discovery Sleep. The agreement ... Pillow Mask, and will stabilize and strengthen Airway’s presence with a dedicated, reputable ...
(Date:4/21/2017)... ... , ... Providing for loved ones before one’s passing is of paramount importance. ... begin. “Now more than ever there are some questions that are far too critical ... said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: